DBVT
DBV Technologies
Halal Rating :
Last Price
$4.59
Last updated:
Market Cap
-
7D Change
-15.16%
1 Year Change
427.59%
Company Overview
Industries
Exchange
Next Earnings Date
DBV Technologies is a clinical-stage biopharmaceutical company focused on developing innovative treatments for food allergies. Their lead product candidate, Viaskin Peanut, is an investigational therapy for peanut allergy in children. The company utilizes its proprietary platform technology, Viaskin, which is designed to deliver biologically active compounds to the immune system through intact skin.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $1.07m | $31.4m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $1.16m | $35.0m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $1.41m | $29.96m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate DBV Technologies's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.